Improved Membrane Chromatography Performance
To more effectively recover large molecular weight proteins, such as blood factors and conjugated proteins or viruses and virus-like particles, Sartorius Stedim Biotech (SSB) has reconfigured its Sartobind membrane chromatography capsules. A range of capsule sizes with a 4 mm bed height is now available from the 1 mL
nano unit up to the new 2.5 L jumbo version.
The capsules’ upstream flow channels have been optimized, and an internal core forms a miniaturized downstream channel, resembling that in existing 8 mm bed height capsules. The new Q, S and salt-tolerant STIC PA ion exchanger capsules, all with a 4 mm bed height, increase dynamic binding capacity by approximately 15% and reduce void volumes by approximately 40% compared with their predecessors, while maintaining high flow rates of 10–30 membrane volumes per minute.
By improving breakthrough behavior, subsequent polishing steps to remove DNA, HCP, aggregates and viruses from recombinant proteins are significantly more reliable and, as less buffer is used, Sartobind also reduces operational costs.
“Traditionally, membrane adsorbers have been using available filter housings, often ignoring chromatographic process parameters, such as back-mixing effects and elution volumes. This new generation of membrane adsorber capsules takes these specific requirements into account and reflects substantial progress for bind and elute applications,” commented Dr Fischer-Frühholz, membrane chromatography expert at SSB.
Furthermore, SSB has added new 400 mL and 800 mL Sartobind Q, S and Phenyl capsules with an 8 mm bed height to its portfolio. These optimized capsules increase dynamic binding capacity up to 48% when compared to adsorbers installed in filter housings.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.